Details

Autor(en) / Beteiligte

• Plummer, Erica L
• Bulach, Dieter M
• Murray, Gerald L
• Jacobs, Susan E
• Tabrizi, Sepehr N
• Garland, Suzanne M

Titel

Gut microbiota of preterm infants supplemented with probiotics: sub-study of the ProPrems trial

Ist Teil von

• BMC microbiology, 2018-11, Vol.18 (1), p.184-184, Article 184

Ort / Verlag

England: BioMed Central Ltd

Erscheinungsjahr

2018

Link zum Volltext

Quelle

SpringerLink

Beschreibungen/Notizen

• The ProPrems trial, a multi-center, double-blind, placebo-controlled randomized trial, previously reported a 54% reduction in necrotizing enterocolitis (NEC) of Bell stage 2 or more from 4.4 to 2.0% in 1099 infants born before 32 completed weeks' gestation and weighing < 1500 g, receiving probiotic supplementation (with Bifidobacterium longum subsp. infantis BB-02, Streptococcus thermophilus TH-4 and Bifidobacterium animalis subsp. lactis BB-12). This sub-study investigated the effect of probiotic supplementation on the gut microbiota in a cohort of very preterm infants in ProPrems. Bifidobacterium was found in higher abundance in infants who received the probiotics (AOR 17.22; 95% CI, 3.49-84.99, p < 0.001) as compared to the placebo group, and Enterococcus was reduced in infants receiving the probiotic during the supplementation period (AOR 0.27; 95% CI, 0.09-0.82, p = 0.02). Probiotic supplementation with BB-02, TH-4 and BB-12 from soon after birth increased the abundance of Bifidobacterium in the gut microbiota of very preterm infants. Increased abundance of Bifidobacterium soon after birth may be associated with reducing the risk of NEC in very preterm infants.